Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid

Pei Wen Hsieh, Wei Yu Chen, Ibrahim A. Aljuffali, Chun Che Chend, Jia You Fang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4-phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.

Original languageEnglish
Pages (from-to)4080-4092
Number of pages13
JournalCurrent Medicinal Chemistry
Volume20
Issue number32
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Tranexamic Acid
Skin
Pharmaceutical Preparations
Skin Absorption
hydroquinone
Hyperpigmentation
Hair Follicle
Esterases
Drug Delivery Systems
Dermis
Drug delivery
Epidermis

Keywords

  • Co-drug
  • Hydroquinone
  • Hyperpigmentation
  • Skin targeting
  • Tranexamic acid

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid. / Hsieh, Pei Wen; Chen, Wei Yu; Aljuffali, Ibrahim A.; Chend, Chun Che; Fang, Jia You.

In: Current Medicinal Chemistry, Vol. 20, No. 32, 10.2013, p. 4080-4092.

Research output: Contribution to journalArticle

Hsieh, Pei Wen ; Chen, Wei Yu ; Aljuffali, Ibrahim A. ; Chend, Chun Che ; Fang, Jia You. / Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 32. pp. 4080-4092.
@article{2eef326185814424a17883714d6c3352,
title = "Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid",
abstract = "Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4-phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.",
keywords = "Co-drug, Hydroquinone, Hyperpigmentation, Skin targeting, Tranexamic acid",
author = "Hsieh, {Pei Wen} and Chen, {Wei Yu} and Aljuffali, {Ibrahim A.} and Chend, {Chun Che} and Fang, {Jia You}",
year = "2013",
month = "10",
doi = "10.2174/15672050113109990202",
language = "English",
volume = "20",
pages = "4080--4092",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "32",

}

TY - JOUR

T1 - Co-drug strategy for promoting skin targeting and minimizing the transdermal diffusion of hydroquinone and tranexamic acid

AU - Hsieh, Pei Wen

AU - Chen, Wei Yu

AU - Aljuffali, Ibrahim A.

AU - Chend, Chun Che

AU - Fang, Jia You

PY - 2013/10

Y1 - 2013/10

N2 - Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4-phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.

AB - Hydroquinone and tranexamic acids (TXA) are skin-lightening agents with a hydrophilic nature and low skin absorption. A high dose is needed for clinical use, resulting in a high incidence of skin irritation. Co-drugs formed by conjugating hydroquinone and TXA were synthesized and their in vitro and in vivo skin absorption characteristics were evaluated. The two synthesized co-drugs were 4-hydroxyphenyl 4-(aminomethyl)cyclohexanecarboxylate (HAC) and 1,4-phenylene bis(aminomethyl)cyclohexanecarboxylate (BAC). The co-drugs were chemically stable in aqueous solution, but rapidly degraded to the respective parent drug in esterases and skin homogenates. Compared to hydroquinone application, 7.2- and 2.4-fold increments in the hydroquinone skin deposition were obtained with the in vitro application of HAC and BAC. HAC and BAC led to 3- and 2-fold enhancements of equivalent TXA deposition compared to TXA administration. The in vivo experiment showed a further enhancement of co-drugs compared to the in vitro setup. The transdermal penetration of co-drugs, especially BAC, was much lower than that of hydroquinone and TXA. This indicated high-level skin targeting by the co-drugs. HAC and BAC revealed strong affinities for the viable epidermis/dermis. Hair follicles are important reservoirs for co-drug delivery. Daily administration of co-drugs to the skin did not generate irritation for up to 7 days. Both co-drugs are superior candidates for treating skin hyperpigmentation.

KW - Co-drug

KW - Hydroquinone

KW - Hyperpigmentation

KW - Skin targeting

KW - Tranexamic acid

UR - http://www.scopus.com/inward/record.url?scp=84887892588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887892588&partnerID=8YFLogxK

U2 - 10.2174/15672050113109990202

DO - 10.2174/15672050113109990202

M3 - Article

C2 - 23931279

AN - SCOPUS:84887892588

VL - 20

SP - 4080

EP - 4092

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 32

ER -